STAT+: Lilly’s Ajax acquisition may have been worth it

STAT PlusNewsletterThe Readout Lilly’s Ajax acquisition may have been worth it A syphilis drug shortage, Sanofi’s diabetes drug approval, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanJune 15, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. A worsening shortage of Bicillin, Pfizer’s injectable form of penicillin, left an Arizona woman unable to receive timely treatment for syphilis during pregnancy.Advertisement Also, the FDA approved Sanofi’s diabetes drug Tzield after an unusually contentious review process, and the Trump administration has proposed closing a Medicare negotiation loophole. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout June 12, 2026 STAT Plus: Prometheus raises $12 billion in capital for artificial engineers The Readout LOUD June 11, 2026 STAT Plus: An obesity drug deep-dive, and peptides move mainstream Advertisement The Readout June 11, 2026 STAT Plus: Novartis doubles down on molecular glue strategy Biotech June 11, 2026 STAT Plus: Enliven Therapeutics’ leukemia drug shows promise in new study Adam's Biotech Scorecard June 11, 2026 STAT Plus: ‘Synthetic lethality’ could trigger another round of biotech M&A Subscriber Picks